Literature DB >> 34864960

Updates from the American Heart Association Scientific Sessions: cardiovascular pharmacotherapy.

Husam M Salah1, Allison P Levin2, Marat Fudim3,4.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 34864960      PMCID: PMC9071404          DOI: 10.1093/ehjcvp/pvab084

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


× No keyword cloud information.
  2 in total

1.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Authors:  Stefan D Anker; Javed Butler; Gerasimos Filippatos; João P Ferreira; Edimar Bocchi; Michael Böhm; Hans-Peter Brunner-La Rocca; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure-Valenzuela; Nadia Giannetti; Juan Esteban Gomez-Mesa; Stefan Janssens; James L Januzzi; Jose R Gonzalez-Juanatey; Bela Merkely; Stephen J Nicholls; Sergio V Perrone; Ileana L Piña; Piotr Ponikowski; Michele Senni; David Sim; Jindrich Spinar; Iain Squire; Stefano Taddei; Hiroyuki Tsutsui; Subodh Verma; Dragos Vinereanu; Jian Zhang; Peter Carson; Carolyn Su Ping Lam; Nikolaus Marx; Cordula Zeller; Naveed Sattar; Waheed Jamal; Sven Schnaidt; Janet M Schnee; Martina Brueckmann; Stuart J Pocock; Faiez Zannad; Milton Packer
Journal:  N Engl J Med       Date:  2021-08-27       Impact factor: 176.079

2.  Milvexian for the Prevention of Venous Thromboembolism.

Authors:  Jeffrey I Weitz; John Strony; Walter Ageno; David Gailani; Elaine M Hylek; Michael R Lassen; Kenneth W Mahaffey; Ravi S Notani; Robin Roberts; Annelise Segers; Gary E Raskob
Journal:  N Engl J Med       Date:  2021-11-15       Impact factor: 176.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.